The development of multiplex companion diagnostics is driven by the need to understand efficacy and safety at both the molecular and phenotypic levels. In the future, personalized therapeutic regimens will be tailored to each patient’s genomic, transcriptomic, and epigenomic profiles to optimize individual outcomes.
For personalized (or precision) medicine to become a sustaining reality, all stakeholders—patients, healthcare professionals, drug development companies, regulatory agencies and payers—must work together.
Advancing multiplex companion diagnostics technology… Read More »
ITHACA, N.Y. – Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp. (NASDAQ: LIFE), a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.
Technology developed by Rheonix for the molecular diagnostics market, including the Rheonix CARD® , a disposable cartridge the size of a credit card… Read More »
ITHACA, N.Y. – Widespread implementation of personalized medicine will depend upon identification of clinically relevant biomarkers, cost-effective methods to detect them and a reimbursement strategy that will meet the needs of all stakeholders.
These will be a few of the points raised during a workshop entitled “Implementing Effective and Reimbursable Personalized Medicine” at the upcoming joint annual meeting of the American Association for Clinical Chemistry (AACC) and the American Society for… Read More »
ITHACA, N.Y. – The discovery and development of microfluidic sensors hold great promise for the design of revolutionary diagnostic devices capable of complex analysis, in a disposable format, with minimal user intervention. However, many devices in this category have faced challenges to their widespread adoption.
Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, has successfully navigated the technological hurdles and solved many of the challenges in this area.… Read More »
ITHACA, N.Y. –– Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has added Frank Gill as vice president of manufacturing. In this role, Gill will be responsible for formulating and executing the company’s operations strategy as it scales from prototype volumes to fully automated production of life science and in vitro diagnostics products.
Gill will oversee manufacturing of Rheonix instrument platforms, reagent kits, and the Rheonix CARD® system, a… Read More »
ITHACA, N.Y. – While advancements in genetic testing have enabled rapid, more sensitive and specific methods to aid in the diagnoses and appropriate treatment of diseases including cancer, hemophilia, sickle cell anemia and cystic fibrosis, such advancements can come at a cost to both health care providers and patients. Molecular diagnostics executive Richard Montagna, Ph.D., vice president for scientific affairs for Rheonix Inc., an Ithaca-based developer of an automated molecular… Read More »
ITHACA, N.Y. –– Rheonix Inc., the developer of automated molecular diagnostic testing platforms, has been issued a patent protecting self-contained instruments for purifying, amplifying, and analyzing one or more target nucleic acid sequences necessary for performing a molecular test. The claims of the patent protect Rheonix’s EncompassMDx™ instrument. The instrument performs a wide range of molecular analyses using the Rheonix CARD® , which received international patent protection in 2012.
When used… Read More »
ITHACA, N.Y. –– Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, added two new members to its management team. Steve Pemberton joins the company as vice president of marketing and sales, and Bryan Greene was named director of consumable manufacturing. These appointments will help Rheonix manufacture, launch, market and distribute its EncompassMDx™ molecular platform and associated Rheonix CARD® assays.
“I am very excited we have brought Steve and Bryan… Read More »
How have automation needs changed in the past few years?
Plank: In molecular testing, the desire among labs for greater efficiencies has increased the demand for automation and workflow advancements. More and more, labs are asking for platforms that offer more menu selection with less testing equipment. So the pattern of consolidation of platforms and menus is the same technological evolution we've seen over the last several years in clinical chemistry… Read More »
ITHACA, N.Y. – Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has appointed Bill Colston, Ph.D., to its board of directors. Colston, former CEO of QuantaLife Inc., led the development and product launch of Droplet Digital PCR™, a genetic analysis system for quantifying DNA molecules, until his company was acquired by Bio-Rad Laboratories in 2011.
As QuantaLife CEO, Colston raised multiple rounds of private funding and grew the company… Read More »